Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial

被引：0
|
作者：
Wang, S. [1 ]
Hong, R. [2 ]
Xu, F. [2 ]
Xia, W. [2 ]
Teng, Y. [3 ]
Ouyang, Q. [4 ]
Yuan, Z. [2 ]
Jiang, K. [2 ]
Lin, Y. [5 ]
Liu, X. [6 ]
Chen, Q. [7 ]
Wu, X. [8 ]
Shi, Y. [2 ]
Huang, J. [2 ]
An, X. [2 ]
Xue, C. [2 ]
Bi, X. [2 ]
Zheng, Q. [2 ]
Chen, M. [2 ]
Li, H. [9 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China
[4] Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Peoples R China
[6] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China
[7] Guangdong Prov Chinese Med Hosp, Dept Breast, Guangzhou, Peoples R China
[8] Hubei Canc Hosp, Dept Breast, Wuhan, Peoples R China
[9] Sichuan Canc Hosp, Dept Breast Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [21] Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)
    Blakely, L. J.
    Schwartzberg, L. S.
    Wang, G.
    Somer, B. G.
    Wheeler, B. M.
    Stepanski, E. J.
    Walker, M.
    Johns, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor
    Tao, Jessica
    Chen, Ruizhe
    Blackford, Amanda L.
    Cescon, Terrence
    Christou, Antonios
    Couzi, Rima
    Darga, Elizabeth
    Jones, Mary Kate
    Mahosky, Justin
    Nunes, Raquel
    Paoletti, Costanza
    Santa-Maria, Cesar Augusto
    Smith, Karen L.
    Truica, Cristina I.
    Werner, Jeanine
    Wolff, Antonio C.
    Stearns, Vered
    Hayes, Daniel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
  • [24] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [25] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [26] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [27] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [28] Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    Yeo, Belinda
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 14
  • [29] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Kamei, Keitaro
    Noguchi, Yoshinori
    Usami, Eiseki
    Yoshimura, Tomoaki
    ONCOLOGY, 2024,
  • [30] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
12345